Asia Pacific Traumatic Brain Injury Treatment Market
시장 규모 (USD 10억)
연평균 성장률 :
% 
USD
792.23 Billion
USD
1.44 Billion
2024
2032
 예측 기간 |
2025 –2032 |
 시장 규모(기준 연도) |
USD 792.23 Billion |
 시장 규모(예측 연도) |
USD 1.44 Billion |
 연평균 성장률 |
% |
| 주요 시장 플레이어 |
아시아 태평양 외상성 뇌 손상 치료 시장 세분화, 치료(수술, 응급 처치, 약물), 투여 경로(비경구, 경구 및 기타), 환자 연령(소아, 청소년, 노인), 성별(남녀), 손상 원인(낙상, 교통사고, 스포츠 및 기타), 최종 사용자(병원, 신경과 클리닉, 독립 약국 및 기타) - 2032년까지의 산업 동향 및 전망
외상성 뇌 손상 치료 시장 규모
- 아시아 태평양 외상성 뇌 손상 치료 시장은 2024년에 7,922억 3천만 달러 규모로 평가되었으며 2032년에는 14억 4천만 달러 에 이를 것으로 예상됩니다.
- 2025년부터 2032년까지의 예측 기간 동안 시장은 외상성 뇌 손상(TBI) 발생률 증가에 따라 주로 7.9%의 CAGR로 성장할 것으로 예상됩니다.
- 이러한 성장은 외상성 뇌 손상(TBI) 발생률 증가, TBI 치료에 최소 침습적 시술 도입 증가, 외상성 뇌 손상 치료 수요 증가와 같은 요인에 의해 촉진됩니다.
외상성 뇌 손상 치료 시장 분석
- 외상성 뇌 손상(TBI) 치료 시장은 TBI에 대한 인식 증가 , 진단 기술 의 발전 , 사고 및 스포츠 관련 부상 발생률 증가로 인해 상당히 확대될 것으로 예상되며, 효과적인 치료 옵션과 재활 요법에 대한 수요가 증가하고 있습니다.
- 시장에서는 신경 보호제, 줄기 세포 치료, 첨단 재활 기술을 포함한 혁신적인 치료법이 급증하고 있으며 , 이를 통해 회복 결과가 향상되고 TBI 환자의 치료 환경이 확대되고 있습니다.
- 미국은 첨단 의료 인프라, 상당한 연구 투자, 높은 TBI 유병률로 인해 외상성 뇌 손상 치료 시장에서 우위를 점하는 국가 중 하나로 두각을 나타내고 있습니다.
보고서 범위 및 외상성 뇌 손상 치료 시장 세분화
|
속성 |
외상성 뇌 손상 치료 시장 통찰력 |
|
다루는 세그먼트 |
|
|
포함 국가 |
아시아 태평양
|
|
Key Market Players |
|
|
Market Opportunities |
|
|
Value Added Data Infosets |
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework. |
Traumatic Brain Injury Treatment Market Trends
“Growing Adoption of Telemedicine in TBI Treatment”
- Telemedicine allows patients to receive remote consultations and rehabilitation services, improving access to specialized care for individuals in rural or underserved areas, thus facilitating timely intervention for TBI patients
- Utilizing telehealth reduces the costs associated with in-person visits, including travel expenses and lost productivity, making it a financially viable option for both patients and healthcare providers
- In March 2021, NCBI stated that Telehealth visits for patients with acquired brain injuries and their caregivers can ease the burden of transportation, improve compliance, and increase overall satisfaction. Management strategies are largely unaffected in the telehealth setting, and telerehab options have been found to be equal or superior to in-person therapy to treat many associated deficits
- Telemedicine platforms enable continuous monitoring and follow-up care, allowing healthcare professionals to track patient progress remotely, provide real-time feedback, and adjust treatment plans as necessary, ultimately enhancing patient outcomes in TBI management
Traumatic Brain Injury Treatment Market Dynamics
Driver
“Increasing Incidence of Traumatic Brain Injury (TBI)”
- As the number of cases continues to rise due to various contributing factors such as road accidents, sports-related injuries, and falls, particularly among the elderly population. Road traffic accidents remain one of the leading causes of TBI worldwide, with the growing number of vehicles on the road, reckless driving behaviours
- Sports-related injuries, particularly in contact sports like football, boxing, and rugby, have further fueled the surge in TBI cases, with increasing awareness of concussion-related complications prompting the need for advanced treatment solutions
For instance,
- In March 2025, as per the article published by ScienceDirect, there were 20.84 million incident cases and 37.93 million prevalent cases of Traumatic Brain Injury (TBI) globally, leading to 5.48 million, Years Lived With Disability (YLDs). The rising burden of TBI increases the demand for advanced treatments, driving investments in diagnostics, neurosurgery, and rehabilitation, ultimately fueling the growth of the global TBI treatment market
- In October 2024, according to the data published by Centers for Disease Control and Prevention, In 2021, there were 69,473 TBI-related deaths, and in 2020, approximately 214,110 hospitalizations occurred. This equates to over 586 hospitalizations and 190 deaths per day, with individuals aged 75+ and males being the most affected. The rising burden of TBI necessitates advanced treatment solutions, driving growth in the global TBI treatment market
- Factors such as road accidents, sports injuries, and falls—especially among the elderly—contribute to increase in TBI. Growing awareness and demand for advanced treatments, including neurosurgery, drug therapies, and rehabilitation, are fuelling market expansion and technological advancements in TBI management
Opportunity
“Rising Personalized and Targeted Therapies in Traumatic Brain Injury (TBI)”
- TBI is a highly variable condition influenced by severity, location, and patient-specific factors, making traditional treatments less effective. Advances in biomarker discovery, neuroimaging, and computational modeling help identify distinct injury patterns, enabling more targeted therapies. Pharmacogenomics enhances drug selection and dosing, minimizing side effects while maximizing effectiveness. Personalized rehabilitation strategies, tailored to cognitive and motor impairments, further optimize recovery by aligning treatments with individual healing trajectories
For instance,
- In February 2022, as per NCBI, researchers have discovered genetic risk factors like APOE4 and BDNF Val66Met polymorphisms that impact TBI recovery. By focusing on these variations, personalized treatments can lower harmful biomarkers, enhance neuroprotection, and improve rehabilitation. This approach tailors’ therapies to individual needs, ultimately leading to better long-term functional outcomes for TBI patients
- In February 2024, article by MDPI TBI presents a significant opportunity to enhance patient outcomes. Advancements in biomarker discovery, pharmacogenomics, and neuroimaging enable precision treatments tailored to individual injury profiles. Emerging therapies, including neurostimulation and stem cell treatments, further expand possibilities for effective, patient-specific interventions in TBI management
- Personalized and targeted therapies present a transformative approach to managing Traumatic Brain Injury (TBI) by tailoring interventions to individual genetic and molecular profiles. These strategies focus on specific biomarkers and cellular processes to reduce secondary damage and improve recovery. By optimizing treatment, personalized therapies enhance outcomes and promote long-term functional recovery for TBI patients.
Restraint/Challenge
“Difficulties in Overcoming the Blood-Brain Barrier for TBI Treatment”
- A significant challenge in Traumatic Brain Injury (TBI) treatment is the disruption of the Blood-Brain Barrier (BBB). After a TBI, the Blood-Brain Barrier (BBB )often becomes compromised, allowing harmful substances to enter the brain, which can worsen injury and hinder recovery. This creates difficulty in delivering therapeutic agents effectively, limiting the success of many treatments designed to aid recovery and protect brain tissue.
- Furthermore, restoring the integrity of the Blood-Brain Barrier (BBB) without causing additional harm remains a major challenge. Developing targeted delivery systems that can bypass the damaged barrier without introducing further risks is crucial for improving TBI treatment outcomes.
For instance,
- In January 2022, Springer Nature Publishing Inc reported that Blood-Brain Barrier (BBB) it restricts the delivery of therapeutic agents to the brain. Even when the BBB is compromised after injury, many drugs, particularly large molecules, still struggle to penetrate it, limiting the effectiveness of treatments and complicating targeted therapies.
- In June 2024, nature reviews neurology reported that BBB dysfunction can persist from days to years after TBI, contributing to long-term neurological complications. This dysfunction is linked to oedema, neuroinflammation, and alterations in neuronal networks, complicating treatment strategies and leading to cognitive impairments, depression, and post-traumatic epilepsy, thus challenging effective recovery and therapeutic approaches
- 혈액-뇌 장벽(BBB) 손상은 외상성 뇌손상(TBI) 치료에 있어 심각한 과제로, 효과적인 치료 전달을 제한하고 뇌 손상을 악화시킵니다. 지속적인 BBB 기능 장애는 염증, 뇌부종, 인지 장애 등 장기적인 합병증으로 이어질 수 있습니다. 활성산소 제거 요법과 같은 접근법은 뇌 기능 개선에 유망하지만, BBB 손상의 변동성은 치료 전략을 복잡하게 만듭니다. TBI 치료 결과를 개선하기 위해서는 혁신적인 약물 전달 시스템과 BBB 온전성을 모니터링하는 더 나은 방법이 절실히 필요합니다. 이를 통해 더욱 효과적인 치료를 가능하게 하고 장기적인 신경학적 손상을 줄일 수 있습니다.
외상성 뇌 손상 치료 시장 범위
시장은 치료, 환자 연령, 성별, 부상 원인, 최종 사용자를 기준으로 세분화됩니다.
|
분할 |
하위 세분화 |
|
치료별 |
|
|
환자 연령별 |
|
|
성별에 따라 |
|
|
부상 원인에 따라 |
|
|
최종 사용자별 |
|
외상성 뇌 손상 치료 시장 분석
“중국은 외상성 뇌 손상 치료 시장의 주요 지역입니다.”
- 중국은 첨단 의료 인프라, 뇌 손상 관리에 대한 인식 증가, 연구 개발에 대한 상당한 투자로 인해 외상성 뇌 손상 치료 시장을 주도할 것으로 예상됩니다 .
- 중국은 의료 기술의 발전, 뇌 손상 발생률 증가, 강력한 의료 인프라에 힘입어 외상성 뇌 손상 치료 시장에서 상당한 점유율을 차지하고 있습니다.
“ 중국은 가장 높은 성장률을 기록할 것으로 예상됩니다.”
- 중국은 의료 인프라의 급속한 발전, TBI 관리에 대한 인식 증가, 첨단 신경 보호 요법 및 재활 솔루션 채택 증가에 힘입어 아시아 태평양 외상성 뇌 손상(TBI) 치료 시장에서 가장 높은 성장률을 기록할 것으로 예상됩니다.
- 중국은 인구 고령화로 인해 외상성 뇌 손상을 포함한 신경 질환에 더 취약해짐에 따라 주요 시장으로 부상하고 있습니다. 또한, 교통사고, 스포츠 부상, 군 관련 외상성 뇌손상(TBI) 발생률 증가는 아시아 태평양 외상성 뇌손상(TBI) 치료 시장에서 혁신적인 치료 옵션에 대한 수요를 더욱 촉진하고 있습니다.
외상성 뇌 손상 치료 시장 점유율
시장 경쟁 구도는 경쟁사별 세부 정보를 제공합니다. 여기에는 회사 개요, 회사 재무 상태, 매출 창출, 시장 잠재력, 연구 개발 투자, 신규 시장 진출 계획, 아시아 태평양 지역 진출 현황, 생산 시설 및 시설, 생산 능력, 회사의 강점과 약점, 제품 출시, 제품 종류 및 범위, 응용 분야별 시장 지배력 등이 포함됩니다. 위에 제시된 데이터는 해당 회사의 시장 집중도와 관련된 내용만 포함합니다.
시장에서 활동하는 주요 시장 리더는 다음과 같습니다.
- 화이자(미국)
- 테바 파마슈티컬스 US, Inc. (미국)
- Fresenius SE & Co. KGaA(Fresenius Kabi AG)(독일)
- Viatris Inc. (미국)
- 암닐 파마슈티컬스 LLC. (미국)
- Dr. Reddy's Laboratories Ltd. (인도)
- Sun Pharmaceutical Industries, Inc.(인도)
- 루팡(인도)
- 히크마(요르단)
- Aurobindo Pharma US(인도)
- ICU 의료(미국)
- B. Braun Medical Inc. (독일)
- Alembic Pharmaceuticals Limited(인도)
- Merz Therapeutics(독일)
- Advacare(남아프리카공화국)
- 막지마(인도)
- Jedux Parenteral Private Limited(인도)
- Sagent Pharmaceuticals, Inc. (미국)
- 스위스 파마 나이지리아 리미티드(나이지리아)
외상성 뇌 손상 치료 시장의 최신 동향
- 2024년 2월, 비아트리스와 이도르시아는 다양한 치료 분야에 걸쳐 혁신적인 치료법 개발을 위한 북미 지역 주요 연구 개발 협력 계약을 체결했습니다. 이 파트너십은 이도르시아의 신약 개발 전문성과 비아트리스의 북미 시장 진출을 활용하여 획기적인 치료법 개발을 가속화하고 양사의 파이프라인을 확장하며, 전 세계적으로 충족되지 않은 의료 수요를 해결하려는 양사의 노력을 더욱 강화합니다.
- 2021년 2월, 프레제니우스 카비는 오스트리아 시설을 확장하여 제약 및 의료 기술 분야의 생산 역량과 혁신을 강화했습니다. 이번 확장을 통해 제조 효율성이 향상되고, 중환자 치료 제품의 안정적인 공급이 보장되며, 연구 발전이 촉진됩니다. 생산 능력 증대와 운영 효율성 향상을 통해 프레제니우스 카비는 시장 입지를 강화하고 북미 지역의 증가하는 의료 솔루션 수요를 충족할 수 있게 되었습니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 MARKET END-USER COVERAGE GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 TECHNOLOGY ROADMAP
4.4 VALUE CHAIN ANALYSIS
4.5 OPPUTUNITY MAP ANALYSIS
4.6 REIMBURSEMENT FRAMEWORK
4.7 COST ANALYSIS BREAKDOWN
4.8 PENETRATION AND GROWTH PROSPECT MAPPING: ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET
4.9 KEY PRICING STRATEGIES: ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET
4.1 MICRO AND MACRO-ECONOMIC FACTORS: ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET
5 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING INCIDENCE OF TRAUMATIC BRAIN INJURY (TBI)
6.1.2 GROWING ADOPTION OF MINIMALLY INVASIVE PROCEDURES IN TBI TREATMENT
6.1.3 TECHNOLOGICAL ADVANCEMENT FOR DIAGNOSIS OF TRAUMATIC BRAIN INJURIES (TBI)
6.1.4 ADVANCEMENTS IN NEUROPROTECTION AND PHARMACOTHERAPY FOR TBI TREATMENT
6.2 RESTRAINTS
6.2.1 SHORTAGE OF TRAINED NEUROLOGISTS AND NEUROSURGEONS
6.2.2 HIGH COST OF TRAUMATIC BRAIN INJURY (TBI) TREATMENT
6.3 OPPORTUNITIES
6.3.1 RISING PERSONALIZED & TARGETED THERAPIES IN TRAUMATIC BRAIN INJURY (TBI)
6.3.2 GROWING BRAIN STIMULATION TECHNIQUES IN TRAUMATIC BRAIN INJURY (TBI) TREATMENT
6.3.3 RISING ARTIFICIAL INTELLIGENCE (AI) APPLICATIONS IN DIAGNOSING TRAUMATIC BRAIN INJURY (TBI)
6.4 CHALLENGES
6.4.1 DIFFICULTIES IN OVERCOMING THE BLOOD-BRAIN BARRIER FOR TBI TREATMENT
6.4.2 ABSENCE OF STANDARDIZED TREATMENT PROTOCOLS IN TRAUMATIC BRAIN INJURY MANAGEMENT
7 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT
7.1 OVERVIEW
7.2 SURGERY
7.2.1 BRAIN BLEEDING TREATMENT
7.2.2 REHABILITATION
7.2.3 CLOTTED BLOOD REMOVAL
7.2.4 WINDOW OPENING IN SKULL
7.2.5 REPAIRING SKULL FRACTURES
7.3 IMMEDIATE EMERGENCY CARE
7.4 MEDICATIONS
7.4.1 DIURETICS
7.4.2 ANTI-SEIZURE DRUGS (ANTI-CONVULSANT)
7.4.3 ANALGESIC
7.4.4 COMA-INDUCING DRUGS
7.4.5 ANTI-DEPRESSANTS
7.4.6 ANTI-ANXIETY AGENT
7.4.7 ANTI-PSYCHOTICS
7.4.8 ANTI-COAGULANTS
7.4.9 OTHERS
7.4.9.1 Parenteral
7.4.9.2 Oral
7.4.9.3 Others
8 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE
8.1 OVERVIEW
8.2 CHILDREN
8.3 TEENAGER
8.4 ELDER
9 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER
9.1 OVERVIEW
9.2 MALE
9.3 FEMALE
10 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, CAUSE OF INJURY
10.1 OVERVIEW
10.2 FALLS
10.3 MOTOR VEHICLE TRAFFIC
10.4 SPORTS
10.5 OTHERS
11 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 NEUROLOGY CLINICS
11.4 INDEPENDENT PHARMACIES
11.5 OTHERS
12 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION
12.1 ASIA-PACIFIC
12.1.1 CHINA
12.1.2 JAPAN
12.1.3 INDIA
12.1.4 SOUTH KOREA
12.1.5 AUSTRALIA
12.1.6 SINGAPORE
12.1.7 THAILAND
12.1.8 MALAYSIA
12.1.9 INDONESIA
12.1.10 TAIWAN
12.1.11 NEW ZEALAND
12.1.12 PHILIPPINES
12.1.13 VIETNAM
12.1.14 REST OF ASIA-PACIFIC
13 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: GLOBAL
14 SWOT ANALYSIS
15 COMPANY PROFILES
15.1 PFIZER INC.
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENT
15.2 TEVA PHARMACEUTICALS USA, INC.
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT/NEWS
15.3 FRESENIUS SE & CO. KGAA (FRESENIUS KABI AG)
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENT
15.4 VIATRIS INC.
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENT
15.5 AMNEAL PHARMACEUTICALS LLC
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENT
15.6 ADVACARE PHARMA
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENT
15.7 AUROBINDO PHARMA LIMITED
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENT
15.8 ALEMBIC PHARMACEUTICALS LIMITED
15.8.1 COMPANY SNAPSHOT
15.8.2 REVENUE ANALYSIS
15.8.3 PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPMENT
15.9 B. BRAUN SE
15.9.1 COMPANY SNAPSHOT
15.9.2 PRODUCT PORTFOLIO
15.9.3 RECENT UPDATES
15.1 DR. REDDY’S LABORATORIES LTD.
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PIPELINE PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENT
15.11 ICU MEDICAL, INC.
15.11.1 COMPANY SNAPSHOT
15.11.2 REVENUE ANALYSIS
15.11.3 PRODUCT PORTFOLIO
15.11.4 RECENT DEVELOPMENT/NEWS
15.12 HIKMA PHARMACEUTICALS PLC
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PIPELINE PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.13 JEDUX PARENTERAL PRIVATE LIMITED
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENT
15.14 LUPIN
15.14.1 COMPANY SNAPSHOT
15.14.2 REVENUE ANALYSIS
15.14.3 PRODUCT PORTFOLIO
15.14.4 RECENT DEVELOPMENT
15.15 MERZ THERAPEUTICS
15.15.1 COMPANY SNAPSHOT
15.15.2 PIPELINE PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.16 MAXZIMAA
15.16.1 COMPANY SNAPSHOT
15.16.2 PIPELINE PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENT
15.17 SUN PHARMACEUTICAL INDUSTRIES LTD.
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENT
15.18 SWISS PHARMA NIGERIA LIMITED
15.18.1 COMPANY SNAPSHOT
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENT
15.19 SAGENT
15.19.1 COMPANY SNAPSHOT
15.19.2 PRODUCT PORTFOLIO
15.19.3 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
표 목록
TABLE 1 NON-INVASIVE THERAPEUTIC APPROACHES’ EFFICIENCY IN DIFFERENT PHASES OF TBI
TABLE 2 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 3 ASIA-PACIFIC SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 4 ASIA-PACIFIC SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 5 ASIA-PACIFIC IMMEDIATE EMERGENCY CARE IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 6 ASIA-PACIFIC MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 7 ASIA-PACIFIC MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 8 ASIA-PACIFIC MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 9 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 10 ASIA-PACIFIC CHILDREN IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 11 ASIA-PACIFIC TEENAGER IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 12 ASIA-PACIFIC ELDER IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 13 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 14 ASIA-PACIFIC MALE IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 15 ASIA-PACIFIC FEMALE IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 16 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 17 ASIA-PACIFIC FALLS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 18 ASIA-PACIFIC MOTOR VEHICLE TRAFFIC IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 19 ASIA-PACIFIC SPORTS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 20 ASIA-PACIFIC OTHERS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 21 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 22 ASIA-PACIFIC HOSPITALS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 23 ASIA-PACIFIC NEUROLOGY CLINICS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 24 ASIA-PACIFIC INDEPENDENT PHARMACIES IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 25 ASIA-PACIFIC OTHERS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 26 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 27 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 28 ASIA-PACIFIC SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 29 ASIA-PACIFIC MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 30 ASIA-PACIFIC MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 31 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 32 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 33 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 34 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 35 CHINA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 36 CHINA SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 37 CHINA MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 38 CHINA MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 39 CHINA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 40 CHINA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 41 CHINA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 42 CHINA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 43 JAPAN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 44 JAPAN SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 45 JAPAN MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 46 JAPAN MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 47 JAPAN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 48 JAPAN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 49 JAPAN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 50 JAPAN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 51 INDIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 52 INDIA SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 53 INDIA MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 54 INDIA MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 55 INDIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 56 INDIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 57 INDIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 58 INDIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 59 SOUTH KOREA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 60 SOUTH KOREA SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 61 SOUTH KOREA MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 62 SOUTH KOREA MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 63 SOUTH KOREA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 64 SOUTH KOREA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 65 SOUTH KOREA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 66 SOUTH KOREA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 67 AUSTRALIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 68 AUSTRALIA SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 69 AUSTRALIA MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 70 AUSTRALIA MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 71 AUSTRALIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 72 AUSTRALIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 73 AUSTRALIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 74 AUSTRALIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 75 SINGAPORE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 76 SINGAPORE SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 77 SINGAPORE MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 78 SINGAPORE MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 79 SINGAPORE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 80 SINGAPORE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 81 SINGAPORE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 82 SINGAPORE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 83 THAILAND TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 84 THAILAND SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 85 THAILAND MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 86 THAILAND MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 87 THAILAND TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 88 THAILAND TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 89 THAILAND TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 90 THAILAND TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 91 MALAYSIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 92 MALAYSIA SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 93 MALAYSIA MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 94 MALAYSIA MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 95 MALAYSIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 96 MALAYSIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 97 MALAYSIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 98 MALAYSIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 99 INDONESIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 100 INDONESIA SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 101 INDONESIA MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 102 INDONESIA MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 103 INDONESIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 104 INDONESIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 105 INDONESIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 106 INDONESIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 107 TAIWAN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 108 TAIWAN SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 109 TAIWAN MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 110 TAIWAN MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 111 TAIWAN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 112 TAIWAN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 113 TAIWAN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 114 TAIWAN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 115 NEW ZEALAND TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 116 NEW ZEALAND SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 117 NEW ZEALAND MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 118 NEW ZEALAND MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 119 NEW ZEALAND TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 120 NEW ZEALAND TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 121 NEW ZEALAND TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 122 NEW ZEALAND TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 123 PHILIPPINES TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 124 PHILIPPINES SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 125 PHILIPPINES MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 126 PHILIPPINES MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 127 PHILIPPINES TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 128 PHILIPPINES TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 129 PHILIPPINES TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 130 PHILIPPINES TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 131 VIETNAM TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 132 VIETNAM SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 133 VIETNAM MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 134 VIETNAM MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 135 VIETNAM TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 136 VIETNAM TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 137 VIETNAM TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 138 VIETNAM TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 139 REST OF ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
그림 목록
FIGURE 1 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: MARKET END-USER COVERAGE GRID
FIGURE 9 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: SEGMENTATION
FIGURE 11 INCREASING INCIDENCE OF TRAUMATIC BRAIN INJURY (TBI) IS EXPECTED TO DRIVE THE ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET GROWTH IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 12 SURGERY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET IN THE FORECAST PERIOD OF 2025 & 2032
FIGURE 13 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: EXECUTIVE SUMMARY
FIGURE 14 STRATEGIC DECISIONS
FIGURE 15 DROC ANALYSIS
FIGURE 16 TBI-RELATED DEATHS FROM 2018 TO 2024
FIGURE 17 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY TREATMENT, 2024
FIGURE 18 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY TREATMENT, 2025 TO 2032 (USD THOUSAND)
FIGURE 19 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY TREATMENT, CAGR (2025- 2032)
FIGURE 20 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 21 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY PATIENT AGE, 2024
FIGURE 22 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY PATIENT AGE, 2025 TO 2032 (USD THOUSAND)
FIGURE 23 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY PATIENT AGE, CAGR (2025- 2032)
FIGURE 24 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY PATIENT AGE, LIFELINE CURVE
FIGURE 25 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY GENDER, 2024
FIGURE 26 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY GENDER, 2025-2032 (USD THOUSAND)
FIGURE 27 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY GENDER CAGR (2025-2032)
FIGURE 28 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY GENDER, LIFELINE CURVE
FIGURE 29 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY CAUSE OF INJURY, 2024
FIGURE 30 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY CAUSE OF INJURY, 2025-2032 (USD THOUSAND)
FIGURE 31 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY CAUSE OF INJURY, CAGR (2025-2032)
FIGURE 32 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY CAUSE OF INJURY, LIFELINE CURVE
FIGURE 33 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY END USER, 2024
FIGURE 34 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY END USER, 2025-2032 (USD THOUSAND)
FIGURE 35 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY END USER, CAGR (2025-2032)
FIGURE 36 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 37 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: SNAPSHOT (2024)
FIGURE 38 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: COMPANY SHARE 2024 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
